v3.25.4
Net Loss per Share - Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Numerator:      
Net loss $ (31,080) $ (22,705) $ (25,966)
Less: Net loss attributable to noncontrolling interests (4,106) (4,243) (5,716)
Net loss attributable to vTv Therapeutics Inc. (26,974) (18,462) (20,250)
Net loss attributable to common shareholders of vTv Therapeutics Inc., basic (26,974) (18,462) (20,250)
Net loss attributable to common shareholders of vTv Therapeutics Inc., diluted $ (26,974) $ (18,462) $ (20,250)
Class A Common Stock      
Denominator:      
Weighted average number of vTv Therapeutics Inc. Class A Common Stock, basic (in shares) 8,423,632 5,771,052 2,084,973
Weighted average number of vTv Therapeutics Inc. Class A Common Stock, diluted (in shares) 8,423,632 5,771,052 2,084,973
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic (usd per share) $ (3.20) $ (3.20) $ (9.71)
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, diluted (usd per share) $ (3.20) $ (3.20) $ (9.71)